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Evaluation of Ga-DOTA-(D-Asp)n as 
bone imaging agents: D-aspartic 
acid peptides as carriers to bone
Kazuma Ogawa  1,2, Atsushi Ishizaki1, Kenichiro Takai1, Yoji Kitamura3, Akira Makino4, 
Takashi Kozaka3, Yasushi Kiyono4, Kazuhiro Shiba3 & Akira Odani1
67Ga-DOTA-(L-Asp)11 and 67Ga-DOTA-(L-Asp)14, which have been developed as bone imaging agents, 
showed a high accumulation in bone and a rapid blood clearance in mice. However, peptides composed 
of D-amino acids are more stable in vivo than those composed of their L-equivalents. In this study, 67Ga-
DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14) were synthesized using the Fmoc-based solid-phase methodology 
and evaluated. In hydroxyapatite binding assay, binding of 67Ga-DOTA-(D-Asp)n tended to increase with 
increasing length of the amino acid chain. 67Ga-DOTA-(D-Asp)11 and 67Ga-DOTA-(D-Asp)14 caused a high 
accumulation of radioactivity in the bones of the mice. However, the results for 67Ga-DOTA-(D-Asp)n 
and 67Ga-DOTA-(L-Asp)n were comparable. In urine analyses, the proportion of intact complex after 
injection of 67Ga-DOTA-(D-Asp)14 was significantly higher than that of 67Ga-DOTA-(L-Asp)14. Although 
67Ga-DOTA-(D-Asp)14 was more stable than 67Ga-DOTA-(L-Asp)14, the properties of 67Ga-DOTA-(D-Asp)n 
and 67Ga-DOTA-(L-Asp)n as bone imaging agents may be comparable.
Recently, the performance of X-ray computed tomography (CT) and magnetic resonance imaging (MRI) method 
has been greatly improved, particularly in terms of their spatial resolution and technology for reconstructing 
the acquired images. Nuclear medicine imaging has been considered to be the most sensitive approach for diag-
nosing bone disorders such as bone metastases due to its ability to enable the early detection of abnormalities, 
namely, visualization of lesion sites before anatomical changes. For a long time, 99mTc-methylenediphosphonate 
(99mTc-MDP) and 99mTc-hydroxymethylenediphosphonate (99mTc-HMDP) have been widely used in bone imag-
ing1–5. Because 99mTc has the convenient physical characteristics [moderate half-life (6.01 h) for clinical use, a 
generator-produced radionuclide, and appropriate gamma ray energy for imaging] and imaging methods using 
conventional gamma cameras are simple. 99mTc-MDP and 99mTc-HMDP are complexes of 99mTc with bisphospho-
nate analogs having high affinity for bone since the phosphate groups in the bisphosphonate can be coordinated 
with calcium in hydroxyapatite crystals in bone.
The use of [18F]NaF for bone imaging was initially reported by Blau et al. in 19626 and approved by the US 
Food and Drug Administration in 1972. [18F]NaF accumulates at a high level in bone because of chemisorption 
with the exchange of fluoride anions with the hydroxyl groups in hydroxyapatite [Ca10(PO4)6(OH)2]. However, 
[18F]NaF had not been widely used due to its limited availability and high cost, but it has recently been reeval-
uated. The images obtained using clinical positron emission tomography (PET) generally have high spatial res-
olution and PET/CT scanners have become widely available commercially. Although Even-Sapir et al. reported 
that [18F]NaF PET imaging is significantly more sensitive than 99mTc-MDP planar and 99mTc-MDP single photon 
emission computed tomography (SPECT) imaging7, the problems of limited availability and the high cost of 
cyclotrons have remained unresolved.
In recent years, 68Ga (T1/2 = 68 min) has drawn substantial attention as a positron emission radionuclide 
for clinical PET because of its attractive radiophysical properties, such as reasonable half-life for clinical use; 
it has particularly been used as a generator-produced radionuclide. 68Ga-PET does not require an on-site 
cyclotron because 68Ga can be eluted from the generator on demand. Moreover, as the parent nuclide, 68Ge 
(T1/2 = 271 days) has a long half-life, a generator could be used for a long period. Therefore, the demand for 
68Ga-labeled compounds for the diagnosis of bone disorders, such as bone metastases, has increased. Some new 
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radiogallium-labeled complexes for bone imaging have been developed in recent years8–14. Bisphosphonate 
analogs are used as carriers in these radiogallium-labeled complexes. For example, Fellner et al. reported that 
68Ga-DOTA-conjugated bisphosphonate, 68Ga-BPAMD, showed high uptake in osteoblastic metastatic lesions 
in a first human PET study15. In addition, Suzuki et al. reported that 68Ga-NOTA-conjugated bisphosphonate, 
68Ga-NOTA-BP, showed high bone affinity and rapid blood clearance in animal experiments10.
The acidic amino acid peptides (poly-glutamic and poly-aspartic acids) also have a high affinity for 
hydroxyapatite because side-chain carboxyl groups in the acidic amino acid peptides can be coordinated with 
calcium in hydroxyapatite, and could become carriers delivering drugs to bone16–18. Recently, 1,4,7,10-tetraa
zacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has been used as a chelating site, and Ga-DOTA-conjugated 
aspartic acid peptides [Ga-DOTA-(L-Asp)n], with varying peptide lengths (n = 2, 5, 8, 11, or 14), have been devel-
oped and evaluated using the easy-to-handle radioisotope 67Ga, which has a longer half-life (3.3 days), rather 
than 68Ga19. 67Ga-DOTA-(L-Asp)11 and 67Ga-DOTA-(L-Asp)14 show high affinity for hydroxyapatite, high accu-
mulation in bone, and rapid blood clearance in biodistribution experiments in normal mice. Accordingly, the 
bone/blood ratios of 67Ga-DOTA-(L-Asp)11 and 67Ga-DOTA-(L-Asp)14 are comparable to those of 99mTc-HMDP 
and 67Ga-DOTA-Bn-SCN-HBP (Fig. 1A), a Ga-DOTA-conjugated bisphosphonate, which was developed and 
evaluated in our previous study11. In these Ga-DOTA-conjugated aspartic acid peptide compounds, L-aspartic 
acid is used as the only component of the peptides. However, the peptides composed of D-amino acids could be 
more stable in vivo than the peptides built with L-amino acids because they are not readily recognized by the 
peptidases20. Thus, in this study, 67Ga-DOTA-(D-Asp)n (Fig. 1B) of varying peptide lengths (n = 2, 5, 8, 11, or 
14) were synthesized and evaluated. Moreover, to compare the different acidic amino acids as components of the 
carrier, 67Ga-DOTA-(L-Glu)14 (Fig. 1C) and 67Ga-DOTA-(D-Glu)14 (Fig. 1D) were synthesized and evaluated in 
vitro and in vivo.
Results
Preparation of 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-
(D-Glu)14. 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-(D-Glu)14 
were prepared by complexing DOTA-(D-Asp)n, DOTA-(L-Glu)14, and DOTA-(D-Glu)14 with 67Ga, respectively. 
Radiochemical yields of 67Ga-DOTA-(D-Asp)2, 67Ga-DOTA-(D-Asp)5, 67Ga-DOTA-(D-Asp)8, 67Ga-DOTA-(D-
Asp)11, 67Ga-DOTA-(D-Asp)14, 67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-(D-Glu)14 were 25%, 67%, 74%, 56%, 
51%, 38%, and 68% respectively. After RP-HPLC purification, 67Ga-DOTA-(D-Asp)n, 67Ga-DOTA-(L-Glu)14, 
and 67Ga-DOTA-(D-Glu)14 had radiochemical purities of over 95%. The formation of 67Ga-DOTA-(D-Asp)n, 
67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-(D-Glu)14 complexes were determined by examining the retention times 
in RP-HPLC analyses. The 67Ga-labeled complexes showed identical retention times as the corresponding nonra-
dioactive complexes. The results indicated that the formation of 67Ga-labeled complexes were identical to those of 
nonradioactive Ga complexes, which were determined by MS.
Hydroxyapatite-binding assay. Figure 2 shows the percentage of each 67Ga-DOTA-(D-Asp)n (n = 2, 5, 
8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-(D-Glu)14 bound to hydroxyapatite beads. Binding of each 
67Ga-DOTA-(D-Asp)n to the beads increased with an increasing amount of hydroxyapatite, except for that of 
67Ga-DOTA-(D-Asp)2. Binding of 67Ga-DOTA-(D-Asp)n to hydroxyapatite tended to increase with increasing 
length of amino acid chain. The binding affinities of 67Ga-DOTA-(L-Glu)14 and 67Ga-DOTA-(D-Glu)14 were com-
parable to that of 67Ga-DOTA-(D-Asp)14.
Biodistribution experiments. The biodistribution of 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 
67Ga-DOTA-(L-Glu)14, 67Ga-DOTA-(D-Glu)14, [18F]NaF, and 99mTc-MDP in normal mice is shown in Tables 1–9. 
Among these compounds, 67Ga-DOTA-(D-Asp)8, 67Ga-DOTA-(D-Asp)11, 67Ga-DOTA-(D-Asp)14, 67Ga-DOTA-
(L-Glu)14, 67Ga-DOTA-(D-Glu)14, [18F]NaF, and 99mTc-MDP showed high accumulation and retention of radioac-
tivity in bone. 67Ga-DOTA-(D-Asp)5 showed moderate accumulation of radioactivity in bone; however, the level 
of radioactivity decreased 3 h after injection. 67Ga-DOTA-(D-Asp)2 caused subtle accumulation of radioactivity 
in bone. Although there was little radioactivity in other tissues at 3 h after the injection of 67Ga-DOTA-(D-Asp)n, 
99mTc-MDP, and [18F]NaF because of rapid excretion via the kidneys, the radioactivity in the kidneys after the 
injection of 67Ga-DOTA-(L-Glu)14 and 67Ga-DOTA-(D-Glu)14 was retained.
Urine Analyses. The results of urine analysis using RP-HPLC after injection of 67Ga-DOTA-(L-Asp)14 and 
67Ga-DOTA-(D-Asp)14 showed that a part of these complexes metabolized to more hydrophilic complexes; 
some radioactivity was eluted earlier than the intact complex. The ratio of the intact complex after injection of 
67Ga-DOTA-(D-Asp)14 (85.8 ± 17.4%) was significantly higher than that of 67Ga-DOTA-(L-Asp)14 (55.0 ± 13.9%).
Discussion
It has been shown that the bisphosphonate structure is very useful as a carrier of physiologically active molecules 
or compounds with medicinal properties. This is particularly true for bone lesions because of the high affinity 
of bisphosphonate for hydroxyapatite, which is plentiful in bone but not in soft tissues21,22. Stable radiometal 
complex-conjugated bisphosphonate compounds have been designed as bone-seeking radiopharmaceuticals; 
they have been synthesized and evaluated for the diagnosis and therapy of bone metastases11,23–30. The available 
data show that bisphosphonate is an excellent carrier of radioisotopes to bone lesions. Our recent study has 
shown that L-aspartic acid peptides could also work as carriers of radioisotopes to bone lesions; L-aspartic acid 
peptides have high affinity for hydroxyapatite19,31. Thus, we assumed that D-aspartic acid peptides might be even 
better carriers. They should have a similar degree of affinity for hydroxyapatite but higher stability in vivo than 
the L-aspartic acid compounds.
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In the hydroxyapatite-binding assay, 67Ga-DOTA-(D-Asp)n with a longer amino acid chain showed higher 
affinity for hydroxyapatite than the short-chain compounds. The binding patterns of 67Ga-DOTA-(D-Asp)n were 
almost the same as those of 67Ga-DOTA-(L-Asp)n19. A previous study reported that the dissociation constants and 
the maximal binding rates of Fmoc-peptide compounds for hydroxyapatite show no significant differences among 
Fmoc-(L-Asp)n, Fmoc-(D-Asp)n, and Fmoc-(L-Glu)n (n = 2, 4, 6, 8, 10)32. This is consistent with the results of 
hydroxyapatite binding assay in our study. We found that aspartic acid peptides had the same degree of affinity 
for hydroxyapatite regardless of their optical isomeric form. Moreover, there were no differences between the 
affinities of aspartic acid peptides and glutamic acid peptides for hydroxyapatite.
In in vivo studies, it is known that the peptides that composed of D-amino acids are more stable than the 
L-amino acid peptides20. A study examining the Fmoc compounds reported that, after a single i.v. administration, 
the plasma concentration of Fmoc-(L-Asp)6 decreased more rapidly than the concentration of Fmoc-(D-Asp)6. 
Degradation products did not appear in the plasma after the injection of Fmoc-(D-Asp)6, but Fmoc-(L-Asp)4 and 
Fmoc-(L-Asp)2 were detected in plasma after the injection of Fmoc-(L-Asp)632. Therefore, we had expected to 
Figure 1. Chemical structures of (A) Ga-DOTA-Bn-SCN-HBP, (B) Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 
(C) Ga-DOTA-(L-Glu)14, and (D) Ga-DOTA-(D-Glu)14.
www.nature.com/scientificreports/
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observe increased accumulation in bone after the injection of 67Ga-DOTA-(D-Asp)n, caused by their superior in 
vivo stability. In urine analyses, 67Ga-DOTA-(L-Asp)14 metabolized to more hydrophilic complexes, which should 
be 67Ga-DOTA conjugated with shorter aspartic acid peptides, because of the cleavage of an amide bond in the 
peptide. These compounds were diluted before the full-length compound during the RP-HPLC using an ODS 
column. This indicates that 67Ga-DOTA-(D-Asp)14 is more stable than 67Ga-DOTA-(L-Asp)14. Since 67Ga-DOTA 
conjugated with shorter aspartic acid peptides should show lower accumulation in bone than 67Ga-DOTA conju-
gated with long aspartic acid peptides, we expected that 67Ga-DOTA-(D-Asp)n, which has higher stability, would 
show higher accumulation in bone than 67Ga-DOTA-(L-Asp)n. However, against our expectations, the accumu-
lation of radioactivity in bone was comparable for 67Ga-DOTA-(L-Asp)n and 67Ga-DOTA-(D-Asp)n. Not only 
67Ga-DOTA-(D-Asp)n but also 67Ga-DOTA-(L-Asp)n immediately accumulated in bone or was excreted into 
urine via the kidneys with little degradation; both molecule types showed extremely rapid clearance from the 
blood. There was no difference between the biodistributions of 67Ga-DOTA-(L-Asp)n and 67Ga-DOTA-(D-Asp)n.
To compare the biodistributions of 67Ga-DOTA-conjugated acidic amino acid peptides with the biodistribu-
tions of other typical bone-seeking compounds, biodistribution experiments of 99mTc-MDP and [18F]NaF were 
Figure 2. Binding ratios of 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 67Ga-
DOTA-(D-Glu)14 to hydroxyapatite beads. Data are shown as the mean ± SD for four samples.
Tissue
Time after injection
10 min 60 min 180 min
Blood 2.19 (0.24) 0.24 (0.12) 0.05 (0.03)
Liver 0.57 (0.08) 0.31 (0.27) 0.11 (0.04)
Kidney 7.61 (1.17) 6.33 (4.68) 1.42 (0.59)
Small-intestine 0.50 (0.11) 0.14 (0.08) 0.08 (0.03)
Large-intestine 0.37 (0.08) 0.12 (0.11) 0.38 (0.23)
Spleen 0.50 (0.11) 0.24 (0.14) 0.08 (0.02)
Pancreas 0.57 (0.12) 0.15 (0.06) 0.09 (0.05)
Lung 1.45 (0.23) 0.26 (0.18) 0.08 (0.01)
Heart 0.86 (0.11) 0.11 (0.04) 0.06 (0.03)
Stomachb 0.24 (0.07) 0.06 (0.03) 0.36 (0.58)
Bone (Femur) 1.57 (0.71) 0.88 (0.34) 0.49 (0.04)
Muscle 0.53 (0.05) 0.11 (0.05) 0.08 (0.03)
Brain 0.07 (0.01) 0.02 (0.01) 0.01 (0.01)
F/B ratioc 0.71 (0.27) 3.78 (1.03) 12.80 (8.77)
Table 1. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)2 in micea. aExpressed 
as % injected dose. Each value represents the mean (SD) for five animals. bExpressed as % injected dose. 
cFemur:blood ratio.
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performed. 67Ga-DOTA-(D-Asp)11, 67Ga-DOTA-(D-Asp)14, 99mTc-MDP, and [18F]NaF showed excellent biodis-
tribution as bone imaging agents, such as high bone accumulation and low radioactivity in non-target tissues. 
Among these agents, as [18F]NaF showed the highest bone uptake, [18F]NaF may have the most preferable bio-
distribution as a bone imaging agent. However, the bone/non-target tissue radioactivity ratios of 99mTc-MDP and 
67Ga-DOTA-(D-Asp)n (n = 11 or 14) are sufficient for bone imaging, and 99mTc and 68Ga have some convenient 
physical properties as radionuclides. Thus, 99mTc-MDP and 68Ga-DOTA-(D-Asp)n (n = 11 or 14) should be useful 
in a clinical context.
The 67Ga-DOTA-conjugated L-glutamic acid peptide, 67Ga-DOTA-(L-Glu)14, and the 67Ga-DOTA-conjugated 
D-glutamic acid peptide, 67Ga-DOTA-(D-Glu)14, also showed rapid clearance from the blood and high accu-
mulation in bone, similarly to 67Ga-DOTA-(L-Asp)14 and 67Ga-DOTA-(D-Asp)14. Generally, radiometal-labeled 
peptides tend to show a high accumulation of radioactivity in the kidneys. It has been reported that the accumu-
lation of radioactivity in the kidneys after the injection of 111In-labeled peptides is affected by their molecular 
charges33,34. As the renal brush border membrane is negatively charged, a repulsive force could arise between 
this membrane and negatively charged compounds. Such repulsive force could inhibit the reabsorption of these 
compounds into renal proximal tubular cells. The introduction of negative charges into radiometal-labeled pep-
tides has also been studied to develop a method of decreasing the accumulation of radioactivity in the kidneys35. 
The extremely low accumulation of radioactivity in the kidneys after the injection of 67Ga-DOTA-(L-Asp)14 and 
Tissue
Time after injection
10 min 60 min 180 min
Blood 2.81 (0.73) 0.27 (0.02) 0.13 (0.07)
Liver 0.67 (0.13) 0.22 (0.11) 0.14 (0.03)
Kidney 12.04 (4.05) 6.31 (3.64) 1.45 (0.34)
Small-intestine 0.55 (0.16) 0.23 (0.09) 0.18 (0.19)
Large-intestine 0.47 (0.13) 0.22 (0.27) 0.22 (0.13)
Spleen 0.56 (0.12) 0.16 (0.05) 0.11 (0.03)
Pancreas 0.72 (0.11) 0.25 (0.19) 0.06 (0.00)
Lung 2.03 (0.34) 0.30 (0.11) 0.09 (0.02)
Heart 1.03 (0.29) 0.12 (0.01) 0.06 (0.01)
Stomachb 0.32 (0.06) 0.10 (0.06) 0.48 (0.89)
Bone (Femur) 6.78 (1.84) 5.01 (0.93) 2.80 (0.58)
Muscle 0.68 (0.21) 0.13 (0.03) 0.07 (0.03)
Brain 0.10 (0.05) 0.02 (0.01) 0.01 (0.00)
F/B ratioc 2.41 (0.22) 18.52 (2.59) 25.42 (10.06)
Table 2. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)5 in micea. aExpressed 




10 min 60 min 180 min
Blood 1.94 (0.12) 0.33 (0.05) 0.13 (0.05)
Liver 0.46 (0.06) 0.14 (0.02) 0.11 (0.01)
Kidney 12.79 (9.18) 2.49 (2.15) 1.23 (0.48)
Small-intestine 0.39 (0.06) 0.13 (0.03) 0.10 (0.06)
Large-intestine 0.26 (0.02) 0.05 (0.00) 0.08 (0.01)
Spleen 0.42 (0.02) 0.16 (0.05) 0.09 (0.02)
Pancreas 0.57 (0.06) 0.11 (0.01) 0.08 (0.02)
Lung 1.34 (0.10) 0.26 (0.03) 0.10 (0.03)
Heart 0.63 (0.06) 0.14 (0.07) 0.05 (0.02)
Stomachb 0.34 (0.23) 0.04 (0.01) 0.10 (0.13)
Bone (Femur) 9.86 (1.90) 11.63 (2.57) 12.49 (2.61)
Muscle 0.57 (0.40) 0.15 (0.07) 0.14 (0.16)
Brain 0.05 (0.00) 0.01 (0.01) 0.01 (0.00)
F/B ratioc 5.04 (0.77) 35.96 (13.10) 122.09 (89.13)
Table 3. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)8 in micea. aExpressed 
as % injected dose. Each value represents the mean (SD) for five animals. bExpressed as % injected dose. 
cFemur:blood ratio.
www.nature.com/scientificreports/
6SCIEntIFIC REPORTs | 7: 13971  | DOI:10.1038/s41598-017-14149-7
67Ga-DOTA-(D-Asp)14 may have been caused by their negative charges. We had expected that 67Ga-DOTA-
(L-Glu)14 and 67Ga-DOTA-(D-Glu)14, being negatively charged like 67Ga-DOTA-(L-Asp)14 and 67Ga-DOTA-
(D-Asp)14, would also cause low accumulation of radioactivity in the kidneys. However, contrary to our 
expectations, high accumulation and retention or slower clearance of radioactivity in the kidneys were observed 
after the injection of 67Ga-DOTA-(L-Glu)14 or 67Ga-DOTA-(D-Glu)14. The mechanism behind these phenomena 
are unclear, but we must conclude that the glutamic acid peptides are not appropriate as carriers to the bone in the 
nuclear medicine imaging because of their association with high radioactivity in the kidneys.
In this study, no differences in the biodistributions between L-aspartic acid [67Ga-DOTA-(L-Asp)n] and 
D-aspartic acid [67Ga-DOTA-(D-Asp)n] compounds were observed, presumably because of their extremely rapid 
blood clearance. Recently, we have proposed a new concept of using a bifunctional peptide containing an aspartic 
acid peptide linker as a carrier to bone metastases and an RGD peptide, which has high affinity for αvβ3 integrin, 
as a carrier to primary cancer31. In this compound, L-aspartic acid is used as a composite component of the aspar-
tic acid peptide linker. A D-aspartic acid peptide linker may be effective in the new approach. Higher stability of 
the D-aspartic acid peptide linker should be effective for higher accumulation in target tissues because the blood 
clearance of bifunctional peptide does not occur as rapidly as that of 67Ga-DOTA-(D-Asp)n. Further studies are 
needed to examine the effectiveness of a D-aspartic acid peptide linker in the drug design concept.
Tissue
Time after injection
10 min 60 min 180 min
Blood 2.46 (0.60) 0.09 (0.04) 0.03 (0.01)
Liver 0.51 (0.12) 0.15 (0.04) 0.05 (0.03)
Kidney 8.15 (3.86) 1.21 (0.57) 0.54 (0.12)
Small-intestine 0.55 (0.06) 0.18 (0.04) 0.12 (0.02)
Large-intestine 0.40 (0.06) 0.10 (0.01) 0.20 (0.01)
Spleen 0.48 (0.13) 0.12 (0.03) 0.12 (0.04)
Pancreas 0.88 (0.07) 0.27 (0.04) 0.14 (0.06)
Lung 1.75 (0.47) 0.28 (0.09) 0.03 (0.01)
Heart 0.94 (0.16) 0.18 (0.04) 0.11 (0.03)
Stomachb 0.28 (0.08) 0.07 (0.01) 0.06 (0.01)
Bone (Femur) 11.90 (2.99) 13.03 (0.90) 14.78 (2.34)
Muscle 0.77 (0.15) 0.16 (0.03) 0.16 (0.11)
Brain 0.06 (0.01) 0.01 (0.01) 0.01 (0.00)
F/B ratioc 4.90 (0.70) 180.99 (91.94) 526.37 (130.49)
Table 5. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)14 in micea. aExpressed 




10 min 60 min 180 min
Blood 1.71 (0.21) 0.14 (0.10) 0.08 (0.04)
Liver 0.51 (0.08) 0.20 (0.10) 0.13 (0.06)
Kidney 12.83 (5.61) 2.92 (3.25) 1.00 (0.40)
Small-intestine 0.38 (0.07) 0.07 (0.01) 0.05 (0.01)
Large-intestine 0.28 (0.02) 0.03 (0.01) 0.11 (0.03)
Spleen 0.44 (0.08) 0.13 (0.06) 0.10 (0.02)
Pancreas 0.53 (0.07) 0.09 (0.09) 0.04 (0.01)
Lung 1.24 (0.18) 0.08 (0.01) 0.05 (0.01)
Heart 0.65 (0.11) 0.04 (0.01) 0.03 (0.01)
Stomachb 0.18 (0.03) 0.04 (0.02) 0.02 (0.01)
Bone (Femur) 11.93 (0.55) 15.26 (1.08) 15.45 (1.65)
Muscle 0.58 (0.16) 0.18 (0.10) 0.06 (0.03)
Brain 0.05 (0.01) 0.01 (0.01) 0.02 (0.01)
F/B ratioc 7.01 (0.56) 147.10 (71.25) 248.95 (170.64)
Table 4. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)11 in micea. aExpressed 
as % injected dose. Each value represents the mean (SD) for five animals. bExpressed as % injected dose. 
cFemur:blood ratio.
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Methods
Materials. Electrospray ionization mass (ESI-MS) analyses were performed with a LCQ (Thermo Fisher 
Scientific, Waltham, MA, USA). Matrix assisted laser desorption/ionization-time of flight mass (MALDI-
TOF-MS) analyses were performed with ABI 4800 plus (AB SCIEX, Foster, CA, USA). [67Ga]GaCl3 was 
supplied by Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). [18F]NaF was prepared in Fukui University and trans-
ported to Kanazawa University. [99mTc]Pertechnetate (99mTcO4−) was eluted in saline solution from generators 
(Nihon Medi-Physics Co., Ltd). 99mTc-MDP was prepared by the addition of 99mTcO4− solution into the mix-
ture of MDP (Wako Pure Chemical Industries, Ltd., Osaka, Japan), tin(II) chloride, and ascorbic acid solution. 
1,4,7,10-Tetraazacyclododecane-1,4,7-tris(t-butyl acetate) (DOTA-tris) was purchased from Macrocyclics 
(Dallas, TX, USA). 9-Fluorenylmethoxycarbonyl (Fmoc)-D-Asp(OtBu)-Wang resin, Fmoc-D-Asp(OtBu), and 
Fmoc-L-Glu(OtBu) were purchased from Merck KGaA (Darmstadt, Germany). Fmoc-L-Glu(OtBu)-Wang resin 
and 2-chlorotrityl chloride resin were purchased from Watanabe chemical Industries, LTD. (Hiroshima, Japan). 
Fmoc-D-Glu(OtBu) was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Other reagents were 
of reagent grade and used as received.
Synthesis of DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14). The protected peptidyl resin was manually 
constructed by an Fmoc-based solid-phase methodology using a method described previously19. After 
Tissue
Time after injection
10 min 60 min 180 min
Blood 1.85 (0.47) 0.12 (0.04) 0.05 (0.02)
Liver 0.47 (0.16) 0.13 (0.03) 0.14 (0.04)
Kidney 22.06 (4.67) 26.41 (8.53) 25.14 (3.75)
Small-intestine 0.50 (0.14) 0.13 (0.05) 0.15 (0.09)
Large-intestine 0.37 (0.13) 0.07 (0.01) 0.23 (0.15)
Spleen 0.44 (0.12) 0.10 (0.03) 0.11 (0.06)
Pancreas 0.59 (0.15) 0.13 (0.02) 0.08 (0.02)
Lung 1.57 (0.42) 0.13 (0.03) 0.06 (0.02)
Heart 0.67 (0.22) 0.10 (0.02) 0.06 (0.01)
Stomachb 0.22 (0.03) 0.07 (0.05) 0.07 (0.07)
Bone (Femur) 9.81 (2.35) 11.07 (1.66) 10.90 (1.17)
Muscle 0.63 (0.12) 0.10 (0.05) 0.30 (0.47)
Brain 0.05 (0.01) 0.01 (0.00) 0.03 (0.01)
F/B ratioc 5.41 (0.93) 97.50 (26.27) 239.85 (89.95)
Table 6. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(L-Glu)14 in micea. aExpressed 




10 min 60 min 180 min
Blood 2.09 (0.35) 0.10 (0.02) 0.01 (0.01)
Liver 0.46 (0.07) 0.12 (0.03) 0.08 (0.02)
Kidney 13.43 (3.15) 10.61 (5.38) 6.59 (1.74)
Small-intestine 0.37 (0.03) 0.22 (0.15) 0.15 (0.05)
Large-intestine 0.42 (0.05) 0.18 (0.17) 0.25 (0.12)
Spleen 0.37 (0.06) 0.06 (0.02) 0.03 (0.02)
Pancreas 0.68 (0.26) 0.13 (0.05) 0.06 (0.02)
Lung 1.65 (0.44) 0.13 (0.02) 0.04 (0.01)
Heart 0.79 (0.13) 0.08 (0.02) 0.05 (0.02)
Stomachb 0.29 (0.06) 0.19 (0.11) 0.29 (0.23)
Bone (Femur) 10.98 (0.49) 11.78 (1.21) 12.20 (2.41)
Muscle 0.78 (0.31) 0.19 (0.22) 0.02 (0.01)
Brain 0.05 (0.01) 0.01 (0.00) 0.01 (0.00)
F/B ratioc 5.39 (1.05) 129.55 (40.09) 1179.73 (699.19)
Table 7. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Glu)14 in micea. aExpressed 
as % injected dose. Each value represents the mean (SD) for four animals. bExpressed as % injected dose. 
cFemur:blood ratio.
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the construction of the peptide chain on the resin, the Fmoc protecting group was removed using 20% 
piperidine in dimethylformamide (DMF), and a mixture containing two equivalents of DOTA-tris, 
1,3-diisopropylcarbodiimide (DIPCDI), and 1-hydroxybenzotriazole hydrate (HOBt) in dimethylformamide 
(DMF) was added and allowed to react for 2 h. For the cleavage of peptides from the resin and deprotection, 
0.5 mL of thioanisole and 5 mL of trifluoroacetic acid (TFA) were added to the completely protected peptide resin 
at 0 °C. After stirring at room temperature for 2 h, the resin was removed by filtration, and ether was added to 
the filtrate at 0 °C to precipitate crude peptide. The crude products were purified by reversed-phase (RP)-HPLC 
using a Hydrosphere 5C18 column (10 × 150 mm; YMC, Kyoto, Japan) at a flow rate of 4 mL/min with an iso-
cratic mobile phase of water containing 0.1% TFA [in the case of DOTA-(D-Asp)2] or using a Cosmosil 5C18-AR 
300 column (10 × 150 mm; Nacalai Tesque, Kyoto, Japan) at a flow rate of 4 mL/min with a gradient mobile 
phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min [in the case 
of DOTA-(D-Asp)n (n = 5, 8, 11, or 14)]. UV Chromatograms (220 nm) were obtained. The fraction containing 
DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14) was determined by mass spectrometry and collected. The solvent removal 
from the fraction was performed by freeze-drying to provide DOTA-(D-Asp)n as white powder.
DOTA-(D-Asp)2 MS (ESI): m/z 635 (M + H)+, Yield: 30.4%
DOTA-(D-Asp)5 MS (ESI): m/z 980 (M + H)+, Yield: 39.8%
DOTA-(D-Asp)8 MS (ESI): m/z 1325 (M + H)+, Yield: 11.7%
DOTA-(D-Asp)11 MS (ESI): m/z 1670 (M + H)+, Yield: 12.1%
DOTA-(D-Asp)14 MS (MALDI): m/z 2015 (M + H)+, Yield: 13.6%
Tissue
Time after injection
10 min 60 min 180 min
Blood 1.78 (0.23) 0.11 (0.04) 0.02 (0.00)
Liver 1.34 (0.17) 0.09 (0.02) 0.02 (0.00)
Kidney 5.23 (2.31) 1.13 (0.89) 0.15 (0.08)
Small-intestine 1.31 (0.22) 0.68 (0.10) 0.06 (0.02)
Large-intestine 0.95 (0.22) 1.21 (0.27) 1.39 (0.19)
Spleen 1.10 (0.15) 0.08 (0.02) 0.02 (0.00)
Pancreas 0.87 (0.15) 0.08 (0.08) 0.02 (0.03)
Lung 1.44 (0.19) 0.10 (0.03) 0.03 (0.01)
Heart 1.84 (0.41) 0.15 (0.05) 0.02 (0.01)
Stomachb 0.36 (0.04) 0.06 (0.02) 0.13 (0.14)
Bone (Femur) 27.69 (3.15) 39.96 (2.52) 43.91 (2.64)
Muscle 0.83 (0.13) 0.07 (0.04) 0.01 (0.01)
Brain 0.10 (0.02) 0.36 (0.52) 0.05 (0.02)
F/B ratioc 15.59 (1.01) 381.63 (84.17) 1983.88 (256.88)
Table 8. Biodistribution of radioactivity after i.v. injection of [18F]NaF in micea. aExpressed as % injected dose. 
Each value represents the mean (SD) for four animals. bExpressed as % injected dose. cFemur:blood ratio.
Tissue
Time after injection
10 min 60 min 180 min
Blood 2.43 (0.10) 0.23 (0.04) 0.05 (0.01)
Liver 0.61 (0.02) 0.27 (0.05) 0.16 (0.04)
Kidney 10.44 (1.56) 2.03 (0.50) 1.22 (0.36)
Small-intestine 0.69 (0.15) 1.55 (1.68) 0.26 (0.08)
Large-intestine 0.61 (0.20) 0.14 (0.04) 0.23 (0.07)
Spleen 0.54 (0.07) 0.14 (0.02) 0.07 (0.01)
Pancreas 0.77 (0.10) 0.13 (0.02) 0.07 (0.01)
Lung 1.80 (0.16) 0.30 (0.03) 0.10 (0.02)
Heart 0.94 (0.05) 0.16 (0.02) 0.07 (0.02)
Stomachb 0.63 (0.14) 0.70 (0.37) 0.29 (0.07)
Bone (Femur) 20.76 (1.51) 27.92 (3.25) 29.03 (2.12)
Muscle 0.57 (0.09) 0.13 (0.04) 0.06 (0.01)
Brain 0.06 (0.01) 0.02 (0.00) 0.01 (0.00)
F/B ratioc 8.54 (0.57) 120.87 (9.30) 546.64 (91.83)
Table 9. Biodistribution of radioactivity after i.v. injection of 99mTc-MDP in micea. aExpressed as % injected 
dose. Each value represents the mean (SD) for four animals. bExpressed as % injected dose. cFemur:blood ratio.
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Synthesis of DOTA-(L-Glu)14. A resin-binding protected peptide was constructed by same procedure as 
mentioned above using Fmoc-L-Glu(OtBu)-Wang resin, Fmoc-L-Glu(OtBu), and tris-DOTA. For the cleavage 
of peptides from the resin and the deprotection, 0.5 mL of thioanisole and 5 mL of TFA were added to the fully 
protected peptide resin at 0 °C. After stirring at room temperature for 2 h, the crude product was purified by 
RP-HPLC at a flow rate of 4 mL/min with a gradient mobile phase from water containing 0.1% TFA to 20% 
methanol in water containing 0.1% TFA for 20 min. The solvent removal from the fraction was performed by 
freeze-drying to provide DOTA-(L-Glu)14 and as white powder.
DOTA-(L-Glu)14 MS (ESI): m/z 2212 (M + H)+, Yield: 14.6%
Synthesis of DOTA-(D-Glu)14. Fmoc-D-Glu(OtBu) (4 molar equivalents to resin) was dissolved in dichlo-
romethane. 2-Chlorotrityl chloride resin and N,N-diisopropylethylamine (DIEA, 3.5 equiv.) were added. The 
reaction mixture was rotated for 1 h, and 1 mL of methanol was added to react further for 30 min at room temper-
ature. Construction, cleavage, deprotection, and purification of the peptide were performed by the same proce-
dure as mentioned above. DOTA-(D-Glu)14 was obtained as white powder.
DOTA-(D-Glu)14 MS (ESI): m/z 2212 (M + H)+, Yield: 2.1%
Preparation of Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), Ga-DOTA-(L-Glu)14, and Ga-DOTA-
(D-Glu)14. Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), Ga-DOTA-(L-Glu)14, and Ga-DOTA-(D-Glu)14 were 
synthesized using a method described previously19.
Ga-DOTA-(D-Asp)2 MS (ESI): m/z 701 (M)+
Ga-DOTA-(D-Asp)5 MS (ESI): m/z 1046 (M)+
Ga-DOTA-(D-Asp)8 MS (ESI): m/z 1391 (M)+
Ga-DOTA-(D-Asp)11 MS (ESI): m/z 1736 (M)+
Ga-DOTA-(D-Asp)14 MS (MALDI): m/z 2081 (M)+
Ga-DOTA-(L-Glu)14 MS (ESI): m/z 2278 (M)+
Ga-DOTA-(D-Glu)14 MS (ESI): m/z 2278 (M)+
Preparation of 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 
67Ga-DOTA-(D-Glu)14. Approximately 50 μg of DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), DOTA-(L-Glu)14 
or DOTA-(D-Glu)14 was dissolved in 75 μL of 0.2 M ammonium acetate buffer (pH 5.0), and 25 μL of 67GaCl3 
solution (1.85 MBq) in 0.01 M HCl was added and allowed to react at 80 °C for 8 min. 67Ga-labeled peptides 
were purified by RP-HPLC performed using a Hydrosphere 5C18 column (4.6 × 250 mm; YMC) at a flow rate 
of 1 mL/min with an isocratic mobile phase of water containing 0.1% TFA [in the case of 67Ga-DOTA-(D-Asp)2] 
or using a Cosmosil 5C18-AR 300 column (4.6 × 150 mm) at a flow rate of 1 mL/min with a gradient mobile 
phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min [in the case of 
67Ga-DOTA-(D-Asp)n (n = 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, and 67Ga-DOTA-(D-Glu)14].
Preparation of [18F]NaF. No-carrier-added [18F]fluoride was produced via the 18O(p,n)18F reaction 
from > 98% enriched [18O]water (Taiyo Nippon Sanso Corporation, Tokyo, Japan) on an RDS eclipse RD/HP 
medical cyclotron (Siemens, Knoxville, TN, USA). [18F]NaF was prepared by eluting [18F]fluoride trapped on an 
anion exchange column (QMA Plus Light; Waters Corporation, Milford, MA, USA) with saline after washing the 
anion exchange column with water.
Hydroxyapatite-binding assays. Hydroxyapatite-binding assays were performed in accordance with pre-
viously described procedures19,25. In brief, hydroxyapatite beads (Bio-Gel; Bio-Rad, Hercules, CA, USA) were 
suspended in Tris/HCl-buffered saline (50 mM, pH 7.4) at 2.5 mg/mL, 10 mg/mL, and 25 mg/mL. For the solu-
tions of 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 67Ga-DOTA-(L-Glu)14, or 67Ga-DOTA-(D-Glu)14, ligand 
concentrations were adjusted to 19.5 µM by adding DOTA-(D-Asp)n, DOTA-(L-Glu)14, or DOTA-(D-Glu)14. Two 
hundred microliters of each of 67Ga-DOTA-(D-Asp)n, 67Ga-DOTA-(L-Glu)14, or 67Ga-DOTA-(D-Glu)14 solution 
was added to 200 μL of the hydroxyapatite suspension, and samples were gently shaken for 1 h at room tempera-
ture. After centrifugation at 10,000 g for 5 min, a part of the radioactivity in the supernatants was measured using 
a gamma counter (AccuFLEX γ ARC-7010, Hitachi, Ltd., Tokyo, Japan). Control experiments were performed 
according to the same procedure without hydroxyapatite beads, which showed < 0.1% adsorption of radioactivity 
to vials. The ratios of binding were determined as follows:
Hydroxyapatite binding (%) = (1 − [sample supernatant radioactivity]/[control supernatant radioactivity]) × 100
Biodistribution experiments. Experiments with animals were conducted in strict accordance with the 
Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. The animal experimental proto-
cols used were approved by the Committee on Animal Experimentation of Kanazawa University (Permit Number: 
AP-132633). Biodistribution experiments were performed after intravenous administration of each diluted tracer 
solution (37–740 kBq/100 μL) to 6-week-old male ddY mice (27–32 g, Japan SLC, Inc., Hamamatsu, Japan). Four 
or five mice at each time point after the administration of each compound were sacrificed by decapitation at 10, 
60, and 180 min post-injection. Tissues of interest were taken and weighed. Complete left femurs were isolated as 
representative bone samples, radioactivity was determined using gamma counters (AccuFLEX γ ARC-8001 in the 
case of 18F, Hitachi, Ltd.), and background counts and physical decay were corrected during counting.
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Urine Analyses. 67Ga-DOTA-(L-Asp)14 was prepared according to a method described previously19. 
67Ga-DOTA-(L-Asp)14 or 67Ga-DOTA-(D-Asp)14 solution (370 kBq / 200 μL) was intravenously injected to 
6-week-old male ddY mice. At 1 h post-injection, mice were sacrificed and their urea samples were taken from 
the bladders. After ultrafiltration (Microcon-30, Merck KGaA), the filtrate samples were analyzed by RP-HPLC at 
a flow rate of 1 mL/min with a gradient mobile phase from water containing 0.1% TFA to 20% methanol in water 
containing 0.1% TFA for 20 min.
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